Pradaxa


Pradaxa Lawsuits a Distraction, Says Manufacturer

The German pharmaceutical company responsible for the anticoagulant drug, Pradaxa, offered a $650 million settlement package to wrap up thousands of Pradaxa lawsuits in the U.S. In the statement announcing the proposed settlement, the company, Boehringer Ingelheim, did…

Pradaxa MDL News: Manufacturer Fined for Neglectful Document Handling

In a federal Illinois court, Boehringer Ingelheim has been fined $1 million for neglecting to retain documents pertinent to a multidistrict litigation (MDL). It is unclear if the German pharmaceutical company can be accused of destroying or withholding…

Pradaxa Lawsuit Update: Plaintiffs File Two Motions Proclaiming Defendant Inaction

The latest development in the Pradaxa multidistrict litigation (MDL) in the U.S. District Court for the Southern District of Illinois involves a recently filed court document from mid-September. Both parties convened on September 18, 2013 to discuss issues…

Pradaxa Lawsuit News: Judge Rules to Continue Pradaxa Litigation to Further Examine Effectiveness of Pradaxa Warnings

A plaintiff in a Pradaxa bleeding risk lawsuit was recently granted approval to move forward with his suit. In the Pradaxa lawsuit, the plaintiff claims that the pharmaceutical company behind Pradaxa, Boehringer Ingelheim, did not sufficiently warn users…

Carey Danis & Lowe Pradaxa Lawyers Currently Following Pradaxa MDL 2385

Carey Danis & Lowe Pradaxa lawyers are currently following the Pradaxa multi-district litigation (MDL) in Illinois. The Pradaxa MDL is In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation MDL no. 2385. The Pradaxa MDL is being heard in…

FDA Approves New Anticoagulation Reversal Agent and Boehringer Ingelheim Updates Pradaxa Label

The U.S. Food and Drug Administration (FDA) recently approved a reversal agent to be used in patients experiencing serious and uncontrollable bleeding. The anticoagulation reversal agent is called Kcentra, a product developed and manufactured by CSL Behring. The…

Pradaxa Timeline: Carey Danis & Lowe Pradaxa Lawyers Chronicle Pradaxa Bleeding Risk

August 15, 2009 – Boehringer Ingelheim researchers submitted Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial data to The New England Journal of Medicine October 19, 2010 – Pradaxa approved by FDA to prevent stroke in patients with…

New Pradaxa Analysis Underscores Pradaxa Deaths and Urgency of Further Pradaxa Safety Investigations

In January, the Institute for Safe Medication Practices (ISMP) released a report with their safety analysis of three anticoagulant medications, including Pradaxa, warfarin, and Xarelto. The ISMP found that approximately 1,734 adverse event reports were submitted to the…

Carey Danis & Lowe Examines FDA Pradaxa Safety Review

The U.S. Food and Drug Administration (FDA) recently published a report about the safety of Pradaxa in The New England Journal of Medicine. The article’s intention was to more thoroughly examine the health risks associated with Pradaxa use,…

Pradaxa MDL News: Court Convened for Status Conference in Early February

The Pradaxa multi-district litigation (MDL) met in early February for a status conference to discuss recent progress made in the discovery and deposition processes. According to Seth A. Katz, one of the lawyers representing the plaintiffs in the…

12